FDA's Overreach on Compounded Peptides The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 FDA Approval Unlikely Due to Patent Economics Stefano M. Sinicropi, MD posted on the topic LinkedIn RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica The Peptide Craze Ground Truths Is BPC 157 Banned? Oral vs. Injectable Forms Explained